Archive: (broken) From the post: >>In February 2026, Compass Pathways announced that its synthetic psilocybin compound COMP360 reached the primary goal in a Phase 3 clinical trial for depression that does not respond to standard treatments. Participants who receive one 25 mg dose have fewer symptoms of sadness and hopelessness than those who receive a placebo. To measure this change, researchers use the Montgomery-Asberg Depression Rating Scale (MADRS). This is the first time a therapy based on psilocybin has completed the final testing stage required before a company seeks permission from government agencies to sell it.